There is a peculiar rhythm to public doubt, an almost predictable skepticism that shadows every major public health intervention. In many communities, routine vaccination campaigns are not merely seen as medical efforts but as suspicious obsessions. Why, people ask, does the government keep returning to diseases like polio, measles, or chickenpox as though they are the nation’s only afflictions? Why this relentless emphasis, if not for some hidden agenda. Beneath these questions lies a deeper unease, a mixture of historical distrust, social anxiety, and what scholars in Public Health describe as “institutional credibility gaps”, a condition where even well-intentioned interventions are filtered through suspicion.
This skepticism is not new, nor is it uniquely local. The Health Belief Model, developed by social psychologists in the mid-20th century, explains that people are more likely to reject preventive health measures when they perceive threats as distant, benefits as unclear, or institutions as untrustworthy. In this light, the recurring question: why not malaria, HIV, or poverty?It’s less about logic and more about perception. It reflects what behavioral scientists call “salience bias”: the tendency to focus on the most visible or emotionally charged problems while overlooking the quiet, long-term victories of prevention.
I have encountered this pessimism repeatedly. Some express it subtly, others bluntly, even invoking fears of infertility or population control. In an earlier reflection, I challenged the widespread suspicion surrounding Bill Gates and the Bill & Melinda Gates Foundation, whose global health interventions, particularly in vaccines have been distorted by conspiracy narratives. Instead of recognition for decades of investment in eradicating diseases, what emerges is a paradox: the more ambitious the intervention, the deeper the suspicion. Scholars of Risk Communication argue that in environments saturated with misinformation, trust becomes more valuable than evidence, and once eroded, even truth struggles to find footing. Yet, reality has a way of quietly dismantling myths.
A major development has just emerged in Nigeria’s fight against HIV/AIDS, one that challenges long-held assumptions about the limits of prevention. The arrival of lenacapavir, a long-acting injectable drug administered just twice a year, signals a turning point. Nigeria’s inclusion among the first countries to receive this innovation underscores its strategic importance in the global response. Public health experts suggest that this could revolutionize prevention, particularly among high-risk populations, by overcoming one of the greatest barriers in medicine: adherence.
For decades, adherence has been the Achilles’ heel of HIV prevention strategies. Daily oral pre-exposure prophylaxis (PrEP), though effective, often falters in real-world settings due to forgetfulness, stigma, or access challenges. Lenacapavir changes this equation. By reducing the burden of daily compliance, it aligns with what implementation scientists call the “behavioral feasibility principle”, the idea that the success of a medical intervention depends not only on its biological efficacy but also on how easily it fits into human routines.
This breakthrough arrives at a critical moment. With approximately 1.9 million people living with HIV in Nigeria, and in the face of fluctuating international funding, the stakes could not be higher. For those already on lifelong treatment, the reality is often defined by side effects, opportunistic infections, and the constant vigilance required to prevent transmission. The psychological toll is immense. But prevention innovations like lenacapavir offer a dual promise: to reduce new infections while strengthening the management of existing cases. In epidemiological terms, this is the pathway to “epidemic control”, a state where transmission is sufficiently reduced to no longer constitute a public health crisis. At this point, the lingering question resurfaces: if such breakthroughs are possible, why has it taken so long? Why are vaccines or preventive drugs not available for every disease?
The answer lies in the intricate complexity of biology and economics. Diseases like HIV and hepatitis C evolve rapidly, mutating in ways that evade immune responses, a challenge that has frustrated scientists for decades. Research in Virology highlights how high mutation rates create moving targets, making vaccine development extraordinarily difficult. Similarly, illnesses like malaria and tuberculosis involve complex life cycles or resilient bacterial structures that resist straightforward solutions.
Economic realities further complicate the picture. Vaccine development is not only scientifically demanding but also financially intensive, often requiring billions of dollars and years of trials. Pharmaceutical investment tends to follow market incentives, which means diseases concentrated in low-income regions may receive less attention. This dynamic is well explained by the “market failure” theory in Health Economics, where public health needs do not always align with private sector incentives.
Even when scientific and financial hurdles are overcome, regulatory processes introduce another layer of delay. Safety and efficacy must be rigorously tested across multiple phases before approval, a necessity that ensures public trust but also prolongs timelines. Ironically, the same systems designed to protect people can fuel perceptions of stagnation or neglect.
Meanwhile, the claim that governments ignore diseases like malaria is increasingly difficult to sustain.
Nigeria, for instance, has begun deploying the R21/Matrix-M malaria vaccine alongside the WHO-recommended RTS,S vaccine, targeting children in high-burden areas. Combined with interventions such as insecticide-treated nets and antimalarial therapies, these efforts represent a comprehensive strategy rather than selective attention. The challenge, again, is perception, what people see versus what is actually being done.
Another enduring misconception is the idea that vaccines never seem to end. In reality, vaccination schedules are designed based on immunological evidence, often requiring multiple doses to achieve long-lasting protection. What appears as repetition is, in fact, precision, a carefully calibrated defense against disease. Moreover, national immunization programs cover a wide range of conditions, from tuberculosis and hepatitis B to measles and COVID-19, even if public discourse tends to fixate on a few.
The more troubling myths, however, are those rooted in fear, particularly the claim that vaccines cause infertility. This assertion has been repeatedly examined and debunked through large-scale studies. Within the framework of Evidence-Based Medicine, no credible data supports such a link. On the contrary, vaccination programs across decades have coincided with improved population health and increased life expectancy. Organizations like the World Health Organization and UNICEF continue to affirm vaccine safety based on extensive global surveillance.
From a broader perspective, the prioritization of vaccines is neither accidental nor misplaced. Preventive care is one of the most cost-effective strategies in public health, reducing disease burden, healthcare costs, and economic disruption. Theories of human capital development emphasize that a healthy population is foundational to productivity and national growth. In this sense, vaccination is not separate from poverty alleviation, it is integral to it.
It is also inaccurate to suggest that governments focus solely on vaccines. Public policy operates across multiple domains such as health, education, infrastructure often simultaneously and imperfectly. Vaccination is simply one visible component of a much larger, more complex system of governance.
And so, with the emergence of lenacapavir, one myth quietly collapses. The belief that HIV prevention has stagnated, that nothing new is possible, is no longer tenable. More importantly, this development creates an opening, a moment to confront the broader ecosystem of misinformation, suspicion, and selective perception that has long shaped public discourse.
Progress in science rarely arrives with dramatic declarations; it unfolds incrementally, often unnoticed until its impact becomes undeniable. What we are witnessing now is one such moment, a convergence of innovation, policy, and possibility. If understood clearly, it does more than advance the fight against HIV; it challenges the narratives that have hindered public health efforts for years.
Barka da Sallah and Juma’a Mubarak.
Bagudu can be reached via bagudumohammed15197@gmail.com or 07034943575.
